Palvella Therapeutics will announce 2025 financial results on March 31, 2026, followed by an investor call.
Quiver AI Summary
Palvella Therapeutics, Inc. announced that it will release its full year 2025 financial results on March 31, 2026, before the market opens. Following the release, management will host a conference call at 8:30 a.m. ET to discuss the financial results and provide a corporate update. Investors can access the call via a webcast or by phone through a registration link. Palvella is dedicated to developing therapies for serious, rare skin diseases and vascular malformations that lack FDA-approved treatments. The company’s lead candidate, QTORIN™ rapamycin, is aimed at treating various vascular malformations, while its second candidate, QTORIN™ pitavastatin, targets disseminated superficial actinic porokeratosis. Both products are still in investigational stages and have not received FDA approval.
Potential Positives
- Palvella Therapeutics is set to report its full year 2025 financial results, allowing investors to assess the company's performance and outlook.
- The scheduled conference call demonstrates transparency and commitment to investor relations by providing updates and insights into the company's future direction.
- Palvella's focus on developing therapies for serious, rare skin diseases and vascular malformations positions it in a niche market with potentially high demand and limited competition.
- The company is advancing its product candidates based on the patented QTORIN™ platform, highlighting innovation and the potential for groundbreaking treatments in serious conditions lacking FDA-approved therapies.
Potential Negatives
- Palvella's reliance on investigational therapies that have not been approved by the FDA may raise concerns about the viability and market readiness of their product pipeline.
- The upcoming financial results report on March 31, 2026, may reveal disappointing financial metrics or delays in their development timeline, which could negatively impact investor sentiment.
FAQ
When will Palvella Therapeutics release its 2025 financial results?
Palvella Therapeutics will report its full year 2025 financial results on March 31, 2026, before market open.
How can I access the Palvella conference call?
The conference call can be accessed via a registration link provided in the press release or on Palvella's website.
What is the focus of Palvella Therapeutics?
Palvella Therapeutics focuses on developing therapies for serious, rare skin diseases and vascular malformations.
What are Palvella's key product candidates?
Palvella’s lead candidates include QTORIN™ rapamycin for lymphatic malformations and QTORIN™ pitavastatin for actinic porokeratosis.
Are Palvella's products FDA-approved?
No, Palvella's product candidates QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and are not FDA-approved.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PVLA Insider Trading Activity
$PVLA insiders have traded $PVLA stock on the open market 12 times in the past 6 months. Of those trades, 2 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $PVLA stock by insiders over the last 6 months:
- KATHLEEN GOIN (Chief Operating Officer) has made 0 purchases and 10 sales selling 21,510 shares for an estimated $2,055,146.
- GEORGE M JENKINS purchased 4,000 shares for an estimated $500,000
- ELAINE J HERON purchased 2,400 shares for an estimated $300,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PVLA Hedge Fund Activity
We have seen 93 institutional investors add shares of $PVLA stock to their portfolio, and 47 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC added 354,525 shares (+1016.0%) to their portfolio in Q4 2025, for an estimated $37,108,131
- ADAMS STREET PARTNERS LLC removed 298,986 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $18,743,432
- STATE STREET CORP added 283,211 shares (+206.3%) to their portfolio in Q4 2025, for an estimated $29,643,695
- BVF INC/IL removed 282,240 shares (-24.3%) from their portfolio in Q4 2025, for an estimated $29,542,060
- JENNISON ASSOCIATES LLC added 280,573 shares (+262.4%) to their portfolio in Q4 2025, for an estimated $29,367,575
- ALLIANCEBERNSTEIN L.P. added 269,027 shares (+inf%) to their portfolio in Q4 2025, for an estimated $28,159,056
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 250,062 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $26,173,989
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PVLA Analyst Ratings
Wall Street analysts have issued reports on $PVLA in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/25/2026
- Truist Securities issued a "Buy" rating on 12/16/2025
- Canaccord Genuity issued a "Buy" rating on 12/16/2025
- Clear Street issued a "Buy" rating on 12/05/2025
- Stifel issued a "Buy" rating on 11/24/2025
- Raymond James issued a "Strong Buy" rating on 11/19/2025
- Chardan Capital issued a "Buy" rating on 11/13/2025
To track analyst ratings and price targets for $PVLA, check out Quiver Quantitative's $PVLA forecast page.
$PVLA Price Targets
Multiple analysts have issued price targets for $PVLA recently. We have seen 12 analysts offer price targets for $PVLA in the last 6 months, with a median target of $200.0.
Here are some recent targets:
- Geulah Livshits from Chardan Capital set a target price of $210.0 on 03/16/2026
- Jeet Mukherjee from BTIG set a target price of $215.0 on 02/25/2026
- Graig Suvannavejh from Mizuho set a target price of $250.0 on 02/25/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $255.0 on 02/24/2026
- Whitney Ijem from Canaccord Genuity set a target price of $204.0 on 12/16/2025
- Ritu Baral from TD Cowen set a target price of $133.0 on 12/16/2025
- Danielle Brill from Truist Securities set a target price of $190.0 on 12/16/2025
Full Release
WAYNE, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella” or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the Company will report its full year 2025 financial results before market open on Tuesday, March 31, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update.
To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" section of Palvella’s website. To access the call by phone, please use this registration link , and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company's website at www.palvellatx.com .
About Palvella Therapeutics
Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular malformations, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).
QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
[email protected]
Media
Marcy Nanus
Managing Partner, Trilon Advisors LLC
[email protected]
